Trial Profile
A Phase 1 Clinical Trial to Evaluate Venetoclax With High-dose Ibrutinib for the Treatment of Patients With Chronic Lymphocytic Leukemia With Progressive Disease on Single Agent Ibrutinib.
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 12 May 2023
Price :
$35
*
At a glance
- Drugs Ibrutinib (Primary) ; Venetoclax (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions
- 08 May 2023 Planned primary completion date changed from 1 Aug 2022 to 1 Aug 2023.
- 06 May 2021 Planned primary completion date changed from 1 Aug 2020 to 1 Aug 2022.
- 06 May 2021 Status changed from recruiting to active, no longer recruiting.